Literature DB >> 23872403

Gene therapy approaches to enhance regeneration of the injured peripheral nerve.

Fred de Winter1, Stefan Hoyng2, Martijn Tannemaat3, Ruben Eggers4, Matthew Mason5, Martijn Malessy6, Joost Verhaagen7.   

Abstract

Peripheral nerve injury in humans often leads to incomplete functional recovery. In this review we discuss the potential for gene therapy to be used as a strategy alongside surgical repair techniques for the study of peripheral nerve regeneration in rodent models and with a view to its eventual use for the promotion of successful regeneration in the clinic. Gene therapy can be defined as the introduction of a foreign, therapeutic gene into living cells in order to treat a disease. The first attempts to express a foreign gene in peripheral neurons date back more than 25 years. The vectors used at that time were imperfect-mainly because they contained viral genes that were expressed in the target cells and elicited an immunological response. Fortunately significant progress has been made: today adeno-associated viral vectors can be produced completely free of viral genes and Phase I and II clinical studies have shown that these vectors are well tolerated. The technology for gene delivery has reached a state of readiness for clinical translation in many fields of neurology, including peripheral nerve repair. The current range of potential therapeutic genes for the repair of the traumatized peripheral nerve has also grown over the years and now includes neurotrophic factors with specificities for various subtypes of peripheral neurons, cell adhesion and extracellular matrix molecules and transcription factors. This review for this Festschrift, published to celebrate the 70th birthday of Willem Hendrik Gispen, contains many "footprints" from the time the senior author (JV) worked with Willem Hendrik, first as a student intern, then as a Ph.D. student (1983-1987) and later as a postdoctoral fellow (1989-1993). The preface of this article highlights personal memories of a time that will never come back.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adeno-associated viral vector; Gene therapy; Lentiviral vector; Peripheral nerve

Mesh:

Year:  2013        PMID: 23872403     DOI: 10.1016/j.ejphar.2013.04.057

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Gene delivery to rat and human Schwann cells and nerve segments: a comparison of AAV 1-9 and lentiviral vectors.

Authors:  S A Hoyng; F De Winter; S Gnavi; L van Egmond; C L Attwell; M R Tannemaat; J Verhaagen; M J A Malessy
Journal:  Gene Ther       Date:  2015-05-04       Impact factor: 5.250

2.  Transgenic SCs expressing GDNF-IRES-DsRed impair nerve regeneration within acellular nerve allografts.

Authors:  Xueping Ee; Ying Yan; Daniel A Hunter; Lauren Schellhardt; Shelly E Sakiyama-Elbert; Susan E Mackinnon; Matthew D Wood
Journal:  Biotechnol Bioeng       Date:  2017-05-18       Impact factor: 4.530

3.  Intravascular injections of adenoassociated viral vector serotypes rh10 and PHP.B transduce murine sciatic nerve axons.

Authors:  Hans E Anderson; Kristin L Schaller; John H Caldwell; Richard F Ff Weir
Journal:  Neurosci Lett       Date:  2019-05-09       Impact factor: 3.046

4.  Significant changes in endogenous retinal gene expression assessed 1 year after a single intraocular injection of AAV-CNTF or AAV-BDNF.

Authors:  Chrisna J LeVaillant; Anil Sharma; Jill Muhling; Lachlan Pg Wheeler; Greg S Cozens; Mats Hellström; Jennifer Rodger; Alan R Harvey
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-07       Impact factor: 6.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.